Neurovalens Expands Access to Modius Sleep for Veterans Through U.S. Department of Veterans Affairs (VA) Program

BELFAST, Northern Ireland, Feb. 24, 2025 /PRNewswire/ — Neurovalens, a global leader in noninvasive neurostimulation technology, is making significant strides in addressing chronic insomnia among U.S. veterans. The company’s FDA-cleared, drug-free insomnia treatment device, Modius Sleep, is now available to veterans through the U.S. Department of Veterans Affairs (VA) program.

Insomnia is a significant concern among veterans, with studies showing that nearly 40% of U.S. veterans experience clinical or subthreshold insomnia, a rate far higher than that of the general population (source). Beyond disrupted sleep, insomnia is linked to increased stress, cognitive impairment, and a higher risk of chronic health conditions, making effective solutions critical for veteran well-being. Source: https://jcsm.aasm.org/doi/10.5664/jcsm.9182

Developed by Neurovalens, Modius Sleep is an FDA-cleared, award-winning, drug-free device designed to treat chronic insomnia. Using advanced noninvasive neurostimulation, the device targets key brain regions responsible for sleep regulation, helping users fall asleep faster, stay asleep longer, and improve overall sleep quality.

Jason McKeown, MD, CEO of Neurovalens, commented:
“We are honored to make Modius Sleep available to veterans through the VA program. Sleep issues are a significant challenge for many veterans, and we are proud to offer an effective, drug-free solution that can have a meaningful impact on their health and well-being. This partnership with the VA is a testament to our commitment to improving lives through technology.”

Veterans struggling with chronic insomnia can request Modius Sleep through their local VA healthcare provider or contact Neurovalens directly to explore how this FDA-cleared, drug-free solution can help improve their sleep and overall well-being.

About Modius Sleep
Neurovalens is a global health-tech company specializing in noninvasive neurostimulation solutions designed to address some of the world’s most pressing health challenges. The company’s FDA-cleared Modius technology targets the brain regions responsible for sleep and circadian rhythm regulation, using low-level electrical stimulation of the vestibular nerve to support better sleep, stress management, and overall well-being. Headquartered in Belfast, United Kingdom, Neurovalens is committed to advancing drug-free, neuroscience-driven therapies to improve health outcomes worldwide.

For more information, visit www.neurovalens.com/modiussleep

Contact: Kate Willis
kate.willis@neurovalens.com
+1 513-532-2378

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurovalens-expands-access-to-modius-sleep-for-veterans-through-us-department-of-veterans-affairs-va-program-302382856.html

SOURCE Neurovalens

Staff

Recent Posts

BioSonic Bloom: What Published Research Says About 528 Hz and 432 Hz Audio Frequency Programs

An In-Depth Analysis of Digital Sound Frequency Programs, Binaural Beats Research, and Key Considerations for…

2 hours ago

Best TRT Injection for 2026: Fridays Lists Prescription Testosterone in Injectable and Oral Formats as Men Compare Telehealth Hormone Options

Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research…

2 hours ago

How Does Ozempic Work For Weight Loss? Best Weight Loss Supplement Launch By PhenQ

Ozempic for Weight Loss: Does It Work and Is It Safe? Read PhenQ Details –…

2 hours ago

Best NAD+ Injection for 2026: Sprout Health Lists Compounded NAD+ at $149 First Month as Telehealth Longevity Programs Expand

Prescription NAD+ Injection Access, At-Home Administration Models, Compounding Standards, and What Consumers Should Know Before…

2 hours ago

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

1 day ago